We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Coherus BioSciences: Pure Play In The Emerging Biosimilar In
An SI Board Since January 2015
Posts SubjectMarks Bans Symbol
9 10 0 CHRS
Emcee:  Arthur Radley Type:  Moderated
The following company is how I'm playing this evolving issue for lowering the price for drugs. The company is Coherus Biosciences(CHRS) domiciled in Redwood City, California. The company issued their IPO back in November, 2014, at the price of $13.50 per share. Coherus is a pure play in the emerging biosimilar market for drugs. With Novartis getting FDA approval this week, for the first biosimilar product in the US, this in my opinion opens the door for other companies who have strong analytic skills and management. Coherus has three drugs in development with one in final Phase III testing that should allow them to file their BLA later this year. They also have partnership deals with Baxter and Daiichi-Sanyo. Since going public in November the stock is up more than 65%, but if they get approval of their lead candidate(Humira) the price of the stock at this level would be a bargain.
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
9JP Morgan increased target price to $35 with an overweight rating. (Today)Arthur Radley-2/17/2015
8Was a good presentation! Yesterday and today, I hope is merely a case of profit Arthur Radley-2/11/2015
7CHRS’ Leerink webcast has a good discussion of the pros and cons of the 351(k) pDewDiligence_on_SI-2/11/2015
6Some investors think the PFE-HSP deal is mostly about FoBs, but I would say it’sDewDiligence_on_SI-2/7/2015
5Appears the PFE and Hospira deal caught investor's eye-------at least for yeArthur Radley-2/7/2015
4On reduced volume the stock has pulled back about 20% from recent high, so I douArthur Radley-1/16/2015
3Stock hits new high today ($23.76), being up about 5%. Wonder what it would do iArthur Radley-1/14/2015
2That number of Phase III programs does seem like a tall mountain to climb, but rArthur Radley-1/12/2015
1CHRS says it can start one phase-3 FoB trial every 2 years. (Source: JPM webcastDewDiligence_on_SI-1/12/2015
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):